Adicet Bio (ACET)

• Market cap: $69.6M
• 1 day: -0.96%
• 5 days: 1.54%
• 1 month: -15.11%
• 3 months: -30.09%
• 6 months: -40.03%
• Year to date: -17.8%
• 1 year: -47.27%
• 5 years: -97.1%
• 10 years: -99.62%
• Sector: Healthcare
• Industry: Biotechnology

About: Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.

Employees: 152